Mon, Nov 24, 2014, 7:48 AM EST - U.S. Markets open in 1 hr 42 mins

Recent

% | $
Quotes you view appear here for quick access.

TaxuCardium Pharmaceuticals Group Inc. Message Board

  • franchise_approval franchise_approval Dec 7, 2012 10:34 AM Flag

    CXM Making the Right Decision!!!

    AMRN hiring own sales force and stock drops 20%

    MINYANVILLE ORIGINAL Shares of Amarin (NASDAQ:AMRN) are falling after the drug maker said it will hire a sales force to market its heart medicine derived from pure fish oil rather than partner with another company. Amarin says it is still exploring a strategic partner or outright sale of the company.

    Amarin says it will hire as many as 300 sales representatives to launch the drug Vascepa in the US during the first quarter of 2013. The announcement, made late in the day Thursday, also detailed a $100 million financing the company arranged through an investment fund.

    The company’s shares dropped 20% to $9.60 in early trading Friday. The stock is down by more than a third in the past three months.

    The company is awaiting a decision from US officials on market exclusivity for the drug, a treatment that’s more potent than over-the-counter fish oil products. Vascepa aims to lower triglycerides, a type of fat, in blood.

    MINYANVILLE ORIGINAL Shares of Amarin (NASDAQ:AMRN) are falling after the drug maker said it will hire a sales force to market its heart medicine derived from pure fish oil rather than partner with another company. Amarin says it is still exploring a strategic partner or outright sale of the company.

    Amarin says it will hire as many as 300 sales representatives to launch the drug Vascepa in the US during the first quarter of 2013. The announcement, made late in the day Thursday, also detailed a $100 million financing the company arranged through an investment fund.

    The company’s shares dropped 20% to $9.60 in early trading Friday. The stock is down by more than a third in the past three months.

    The company is awaiting a decision from US officials on market exclusivity for the drug, a treatment that’s more potent than over-the-counter fish oil products. Vascepa aims to lower triglycerides, a type of fat, in blood.

    Sentiment: Strong Buy

 
CRXM
0.2271-0.0379(-14.30%)Nov 21 2:52 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.